Inside AviClear®: The Science, Evidence & What 12 Weeks Looks Like

If you’ve researched laser acne treatment, you’ve encountered AviClear® — usually wrapped in marketing language about treating acne “at the source.” This page strips the marketing away. We’re going to look at exactly how the technology works, what its FDA clearance does and doesn’t mean, what the peer-reviewed clinical evidence actually shows, who’s a genuine candidate, and what a real 12-week course of treatment looks and feels like.

For the broader landscape of laser options, start with our complete guide to laser acne treatment. This page is the deep dive on AviClear specifically.

What AviClear is

AviClear is a laser device made by Cutera that uses a 1726 nanometer wavelength of light to treat acne. What makes it notable is not that it’s a laser — lasers have been used in dermatology for decades — but what it targets: the sebaceous (oil) glands themselves.

Most acne treatments work on the consequences of overactive oil glands — unclogging pores, killing bacteria, calming inflammation. AviClear is designed to work one step upstream, reducing the activity of the glands that produce the oil in the first place. It was the first laser to receive FDA clearance specifically for this approach.

The science: how AviClear works

To understand AviClear, it helps to understand one principle and one number.

The principle: selective photothermolysis

Selective photothermolysis is the foundation of modern laser dermatology. The idea is that a particular wavelength of light can be absorbed strongly by a particular target in the skin — heating and altering that target while leaving surrounding tissue largely unaffected. The art is matching the wavelength to the target.

The number: 1726 nm

The breakthrough behind AviClear is the choice of 1726 nm. Through spectroscopic analysis, researchers identified this wavelength as one preferentially absorbed by the lipids within sebaceous glands. That gives it two important properties:

• It targets oil glands selectively. When 1726 nm light enters the skin, it’s absorbed most strongly by the sebum-rich glands, allowing them to be heated while the surrounding skin is comparatively spared.
• It’s poorly absorbed by melanin. Because 1726 nm isn’t strongly absorbed by pigment, AviClear is considered safe across the full range of skin tones (Fitzpatrick I–VI) — unlike many older lasers that carried real risk for darker skin.

Putting it together: the mechanism

In a treatment, the device delivers 1726 nm energy into the skin while a built-in cooling system (Cutera calls it AviCool™) protects the skin’s surface. The energy is absorbed by the sebaceous glands and converted to heat, which downregulates the glands — reducing their size and how much oil they produce.

This is the key conceptual shift. By reducing oil production at the source, AviClear aims to interrupt the entire acne cascade: less oil means fewer clogged follicles, less fuel for C. acnes, and less inflammation. And because the change is to the glands themselves, the effect is intended to be lasting rather than dependent on daily maintenance.

What AviClear’s FDA clearance actually means

AviClear received FDA clearance in 2022 for the treatment of mild, moderate, and severe inflammatory acne vulgaris, and it was the first energy-based device cleared for this purpose. Clearance applies across skin types.

• “Cleared,” not “approved.” Devices are typically cleared, whereas drugs are approved. Either way, it means the device met the FDA’s regulatory bar for its stated use.
• It indicates a recognized use and safety review — not a guarantee of a specific result for any individual.
• The indication is inflammatory acne. It’s not a clearance for treating scars or pigmentation.

The clinical evidence: what the studies show

The pivotal study (Alexiades et al., 2023)

The central study was published in the Journal of the American Academy of Dermatology in 2023 — a prospective, open-label, single-arm trial of 104 subjects with moderate-to-severe facial acne, spanning Fitzpatrick skin types II–VI. Each received three treatments spaced a few weeks apart. The primary measure was the percentage achieving at least a 50% reduction in inflammatory lesions after the final treatment:

The standout feature is the trajectory: results kept improving from 4 to 12 to 26 weeks — consistent with a durable reduction in oil gland activity. Reported side effects were limited largely to transient acne flare-ups and dryness, and treatment was well tolerated across skin types.

Longer-term data

Follow-up multicenter data extending to one year reported a response rate of approximately 91.5% at 52 weeks, with continued evidence of durability.

Reading the evidence clearly

• These were single-arm studies without a placebo control group — standard for device trials, but a genuine limitation.
• Some of this research was funded by the manufacturer (Cutera). That’s disclosed and common in device development; it’s context, not disqualification.
• The endpoints measure lesion reduction and improvement, not universal, complete clearance. Some people respond dramatically; others more modestly.

Who is a candidate for AviClear?

AviClear may be a strong fit if you:

• Have mild, moderate, or severe inflammatory acne
• Want a treatment that doesn’t depend on remembering daily products
• Prefer to avoid systemic medication, or can’t take it
• Have a skin tone that made older lasers risky
• Understand that results build gradually over a series of sessions

It is not suitable during pregnancy, and is contraindicated for those undergoing treatment for skin cancer. Your provider should also review recent isotretinoin use, medications, and conditions affecting healing. AviClear primarily addresses active acne — existing scars or discoloration are different problems.

What 12 weeks of treatment actually looks like

Before you start: the consultation

Treatment begins with an evaluation. A clinician examines your skin, confirms your acne type and severity, reviews your medical history and medications, and checks for contraindications. This is also the time to get clear, written pricing for your specific plan.

The treatment series: three sessions

AviClear is delivered as a series of three treatments, generally spaced a few weeks apart. A single session usually takes around 30 minutes. During a session, the area is cleansed, then the device is applied delivering 1726 nm energy with simultaneous cooling. Most people describe a warm, prickling or snapping sensation; sensitive spots can feel more intense. Afterward, expect possible mild redness that typically settles within a day or two.

The weeks after: setting expectations

• Improvement is gradual, not instant. The oil glands downregulate over time, so the skin changes over weeks and months.
• A temporary flare is common. Some people break out a bit more shortly after a session before things improve. This is expected.
• The trajectory points up. Results tend to keep improving from the 4-week mark through 12 weeks and well beyond.

Aftercare

Aftercare is usually straightforward: gentle skincare, diligent sun protection, and following your provider’s guidance. Because the laser works internally on the glands, there’s no extensive wound care the way there is with resurfacing.

The takeaway

AviClear represents a real shift in how acne can be treated: a 1726 nm laser that targets the oil glands directly, works across all skin tones, and has peer-reviewed data showing durable, progressive improvement for most patients in its trials. It’s not magic, it’s not right for everyone, and the strongest evidence comes with the usual caveats about single-arm, industry-funded device studies. But for many people, it’s a well-evidenced option worth serious consideration. The way to know if it’s right for you is a consultation.